动脉粥样硬化性心血管疾病风险标志物研究进展

doi:10.3969/j.issn.1673-8640.2021.04.021

摘要/Abstract

摘要：

心血管疾病的发病率高、致残率高、死亡率高,是严重危害人类健康的重大疾病之一。新的动脉粥样硬化性心血管疾病（ASCVD）风险标志物不断被发现,部分生物标志物已成为潜在的干预靶点,这有助于临床对ASCVD患者的准确评估,提高心血管疾病的防治水平。文章对脂类、激素类、炎症类和营养类相关的ASCVD风险标志物进行综述。

关键词: 动脉粥样硬化性心血管疾病, 脂蛋白, 激素, 高敏C反应蛋白, 同型半胱氨酸, 红细胞脂肪酸Omega-3指数

Abstract:

The incidence of cardiovascular diseases is high,the rate of disability is high,and the mortality is high. At present,cardiovascular diseases have become one of the major diseases that seriously endanger human health. Arteriosclerotic cardiovascular disease（ASCVD）risk markers have emerged one after another,and some have become potential targets for intervention. It is helpful for accurate clinical evaluation of patients,which can improve the prevention and treatment of cardiovascular diseases. This review focuses on lipid,hormone,inflammation and nutrition-related ASCVD risk markers.

Key words: Arteriosclerotic cardiovascular disease, Lipoprotein, Hormone, High-sensitivity C-reactive protein, Homocysteine, Omega-3 polyunsaturated fatty acid

中图分类号:

R446.1

汪倩, 朱诗瑶, 陆笛, 朱锟, 吴炯, 全佳丽. 动脉粥样硬化性心血管疾病风险标志物研究进展[J]. 检验医学, 2021, 36(4): 447-452.

WANG Qian, ZHU Shiyao, LU Di, ZHU Kun, WU Jiong, QUAN Jiali. Arteriosclerotic cardiovascular disease risk markers research progress[J]. Laboratory Medicine, 2021, 36(4): 447-452.

图/表 1

参考文献 56

[1]	胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019,34(3):209-220.
[2]	雍伟哲. 《中国成人血脂异常防治指南(2016年修订版)》发布[J]. 中华医学信息导报, 2016,31(20):5.
[3]	ROTH G A, JOHNSON C, ABAJOBIR A, et al. Global,regional,and national burden of cardiovascular diseases for 10 causes,1990 to 2015[J]. J Am Coll Cardiol, 2017,70(1):1-25. DOI URL PMID
[4]	CASTELLI W P. Cholesterol and lipids in the risk of coronary artery disease-the framingham heart study[J]. Can J Cardiol, 1988,4(Suppl A):5A-10A.
[5]	SACHDEVA A, CANNON C P, DEEDWANÍA P C, et al. Lipid levels in patients hospitalized with coronary artery disease:an analysis of 136 905 hospitalizations in get with the guidelines[J]. Am Heart J, 2009,157(1):111-117. e2.
[6]	韩爱忠, 汪俊军. 脂蛋白(a)与心血管疾病的关系[J]. 临床心血管病杂志, 2012,28(9):643-645.
[7]	REINER Z, CATAPANO A L, DE BACKER G, et al. ESC/EAS guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society(EAS)[J]. Eur Heart J, 2011,32(14):1769-1818. DOI URL PMID
[8]	LANGSTED A, NORDESTGAARD B G, KAMSTRUP P R. Elevated lipoprotein(a) and risk of ischemic stroke[J]. J Am Coll Cardiol, 2019,74(1):54-66. DOI URL PMID
[9]	韩旭, 龙明智. PCSK9在血脂调节中的研究进展[J]. 国际心血管病杂志, 2014,41(3):176-178.
[10]	张鹏, 刘梅林. 《2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南》——老年人血脂管理解读[J]. 中国介入心脏病学杂志, 2019,27(9):489-490.
[11]	LANGSTED A, KAMSTRUP P R, NORDESTGAARD B G. High lipoprotein(a) and high risk of mortality[J]. Eur Heart J, 2019,40(33):2760-2770. DOI URL PMID
[12]	GARG P K, ARNOLD A M, HINCKLEY STUKOVSKY K D, et al. Lipoprotein-associated phospholipase A2 and incident peripheral arterial disease in older adults:the cardiovascular health study[J]. Arterioscler Thromb Vasc Biol, 2016,36(4):750-756. DOI URL PMID
[13]	CAI A, LI G, CHEN J, et al. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases:a cross-sectional study of Chinese population[J]. BMC Cardiovasc Disord, 2015,15:14. DOI URL PMID
[14]	LI D, ZHAO L, YU J, et al. Lipoprotein-associated phospholipase A2 in coronary heart disease:review and meta-analysis[J]. Clin Chim Acta, 2017,465:22-29. DOI URL PMID
[15]	ROTELLA DP. SB-480848. GlaxoSmithKline[J]. Curr Opin Investig Drugs, 2004,5(3):348-351. URL PMID
[16]	GREENLAND P, ALPERT J S, BELLER G A, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2010,56(25):e50-e103. DOI URL PMID
[17]	PERK J, DE BACKER G, GOHIKE H, et al. European Guidelines on cardiovascular disease prevention in clinical practice(version 2012). The fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice(constituted by representatives of nine societies and by invited experts)[J]. Eur Heart J, 2012,33(13):1635-1701. DOI URL PMID
[18]	孙艺红, 鄢盛恺. 脂蛋白相关磷脂酶A2临床应用专家建议[J]. 中华心血管病杂志, 2015,43(10):843-847.
[19]	IORGA A, CUNNINGHAM C M, MOAZENI S, et al. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy[J]. Biol Sex Differ, 2017,8(1):33. DOI URL PMID
[20]	CRANDALL C J, HOVEY K M, ANDREWS C A, et al. Breast cancer,endometrial cancer,and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study[J]. Menopause, 2018,25(1):11-20. DOI URL PMID
[21]	ROSSOUW J E, PRENTICE R L, MANSON J E, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause[J]. JAMA, 2007,297(13):1465-1477. DOI URL PMID
[22]	MOSCA L, BENJAMIN E J, BERRA K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update:a guideline from the american heart association[J]. Circulation, 2011,123(11):1243-1262. DOI URL PMID
[23]	ROBINSON J G, FARNIER M, KREMPF M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med, 2015,372(16):1489-1499. DOI URL PMID
[24]	SAVINEAU J P, MARTHAN R, DUMAS DE LA ROQUE E. Role of DHEA in cardiovascular diseases[J]. Biochem Pharmacol, 2013,85(6):718-726. DOI URL PMID
[25]	OHISSON C, LABRIE F, BARRETT-CONNOR E, et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly swedish men[J]. J Clin Endocrinol Metab, 2010,95(9):4406-4414. DOI URL PMID
[26]	MANNELLA P, SIMONCINI T, CARETTO M, et al. Dehydroepiandrosterone and cardiovascular disease[J]. Vitam Horm, 2018,108:333-353. DOI URL PMID
[27]	RIDKER P M, RIFAI N, CLEARFIELD M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[J]. N Engl J Med, 2001,344(26):1959-1965. DOI URL PMID
[28]	KULLER L H, TRACY R P, SHATEN J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial[J]. Am J Epidemiol, 1996,144(6):537-547. DOI URL PMID
[29]	RIDKER P M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention[J]. Circulation, 2003,107(3):363-369. DOI URL PMID
[30]	RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017,377(12):1119-1131. DOI URL PMID
[31]	WILSON P W, PENCINA M, JACQUES P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study[J]. Circ Cardiovasc Qual Outcomes, 2008,1(2):92-97. DOI URL PMID
[32]	万军, 王震, 叶晶, 等. 白细胞介素-6在心血管疾病中的作用及分子机制研究进展[J]. 广西医学, 2017,39(4):513-516.
[33]	BLAKE G J, RIDKER P M. Inflammatory bio-markers and cardiovascular risk prediction[J]. J Intern Med, 2002,252(4):283-294. DOI URL PMID
[34]	ZAMANI P, SCHWARTZ G G, OLSSON A G, et al. Inflammatory biomarkers,death,and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study[J]. J Am Heart Assoc, 2013,2(1):e003103. DOI URL PMID
[35]	RIDKER P M, RIFAI N, STAMPFER M J, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men[J]. Circulation, 2000,101(15):1767-1772. DOI URL PMID
[36]	RIDKER P M, HENNEKENS C H, BURING J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000,342(12):836-843. DOI URL PMID
[37]	KAPTOGE S, SESHASAI S R, GAO P, et al. Inflammatory cytokines and risk of coronary heart disease:new prospective study and updated meta-analysis[J]. Eur Heart J, 2014,35(9):578-589. DOI URL PMID
[38]	KANEKO Y, TAKEUCHI T. IL-6 blockade[J]. Nihon Rinsho, 2016,74(6):963-967. URL PMID
[39]	CAPELLI I, CIANCIOLO G, GASPERONI L, et al. Folic acid and vitamin B12 administration in CKD,why not?[J]. Nutrients, 2019,11(2):383.
[40]	MALLIKETHI-REDDY S, BRIASOULIS A, AKINTOYE E, et al. Novel biomarkers with potential for cardiovascular risk reclassification[J]. Biomarkers, 2017,22(3-4):189-199. DOI URL PMID
[41]	VEERANNA V, ZALAWADIYA S K, NIRAJ A, et al. Homocysteine and reclassification of cardiovascular disease risk[J]. J Am Coll Cardiol, 2011,58(10):1025-1033. DOI URL PMID
[42]	WANG X, QIN X, DEMIRTAS H, et al. Efficacy of folic acid supplementation in stroke prevention:a meta-analysis[J]. Lancet, 2007,369(9576):1876-1882. DOI URL PMID
[43]	BAGGOTT J E, TAMURA T. Homocysteine,iron and cardiovascular disease:a hypojournal[J]. Nutrients, 2015,7(2):1108-1118. DOI URL PMID
[44]	HARRIS W S, VON SCHACKY C. The omega-3 index:a new risk factor for death from coronary heart disease?[J]. Prev Med, 2004,39(1):212-220. DOI URL PMID
[45]	YASUDA S, SHIMOKAWA H. Potential usefulness of fish oil in the primary prevention of acute coronary syndrome[J]. Eur Heart J, 2010,31(1):15-16. DOI URL PMID
[46]	HARRIS W S, DEL GOBBO L, TINTLE N L. The omega-3 index and relative risk for coronary heart disease mortality:estimation from 10 cohort studies[J]. Atherosclerosis, 2017,262:51-54. DOI URL PMID
[47]	LEÓN H, SHIBATA M C, SIVAKUMARAN S, et al. Effect of fish oil on arrhythmias and mortality:systematic review[J]. BMJ, 2008,337:a2931. DOI URL PMID
[48]	KRIS-ETHERTON P M, HARRIS W S, APPEL L J. American Heart Association Nutrition Committee(2002) fish consumption,fish oil,omega-3 fatty acids,and cardiovascular disease[J]. Circulation, 2002,106(21):2747-2757. DOI URL PMID
[49]	HARRIS W S, KRIS-ETHERTON P M, HARRIS K A. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults.[J]. Curr Atheroscler Rep, 2008,10(6):503-509. DOI URL PMID
[50]	WANG T J. Vitamin D and cardiovascular disease[J]. Annu Rev Med, 2016,67:261-272. DOI URL PMID
[51]	GIULIETTI A, VAN ETTEN E, OVERBERGH L, et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-dihydroxyvitamin D(3) works as anti-inflammatory[J]. Diabetes Res Clin Pract, 2007,77(1):47-57. DOI URL PMID
[52]	RIGBY W F, DENOME S, FANGER M W. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA[J]. J Clin Invest, 1987,79(6):1659-1664. DOI URL PMID
[53]	SCRAGG R, JACKSON R, HOLDAWAY I M, et al. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels:a community-based study[J]. Int J Epidemiol, 1990,19(3):559-563. DOI URL PMID
[54]	KILKKINEN A, KNEKT P, ARO A, et al. Vitamin D status and the risk of cardiovascular disease death[J]. Am J Epidemiol, 2009,170(8):1032-1039. DOI URL PMID
[55]	PRINCE R L, AUSTIN N, DEVINE A, et al. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women[J]. Arch Intern Med, 2008,168(1):103-108. DOI URL PMID
[56]	BRAZIER M, GRADOS F, KAMEL S, et al. Clinical and laboratory safety of one year's use of a combination calcium⁺ vitamin D tablet in ambulatory elderly women with vitamin D insufficiency:results of a multicenter,randomized,double-blind,placebo-controlled study[J]. Clin Ther, 2005,27(12):1885-1893. URL PMID

标志物	HR值	干预靶点
Lp（a）	1.50~1.60^[9,10]	PCSK9抑制剂、apo（a）单抗药物^[11]
Lp-PLA2	1.55~1.62^[14]	Lp-PLA2抑制剂,但Ⅲ期临床试验失败^[15]
雌激素	0.61~0.74^[20]	激素替代疗法,雌激素受体调节剂^[22]
DHEA、DHEAS	1.61^[25]	补充DHEA和DHEAS^[26]
hs-CRP	1.08~4.3^[27,28]	IL-1β单克隆抗体^[30]
IL-6	1.25^[37]	托珠单抗^[38]
Hcy	1.79^[36]	补充B族维生素^[37]
ω-3 PUFA指数	0.85^[41]	补充EPA和DHA^[48]
维生素D	0.43^[53]	补充维生素D^[54]

标志物	HR值	干预靶点
Lp（a）	1.50~1.60^[9,10]	PCSK9抑制剂、apo（a）单抗药物^[11]
Lp-PLA2	1.55~1.62^[14]	Lp-PLA2抑制剂,但Ⅲ期临床试验失败^[15]
雌激素	0.61~0.74^[20]	激素替代疗法,雌激素受体调节剂^[22]
DHEA、DHEAS	1.61^[25]	补充DHEA和DHEAS^[26]
hs-CRP	1.08~4.3^[27,28]	IL-1β单克隆抗体^[30]
IL-6	1.25^[37]	托珠单抗^[38]
Hcy	1.79^[36]	补充B族维生素^[37]
ω-3 PUFA指数	0.85^[41]	补充EPA和DHA^[48]
维生素D	0.43^[53]	补充维生素D^[54]